Sugi Predict

Sugi Predict / Targets / UGT1A8

UGT1A8

UDP-glucuronosyltransferase 1A8 · Q9HAW9 · UGT1A8 on Sugi Atlas →

124 patent compounds predicted against UGT1A8, 105 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL12073700 SCHEMBL12073700 1.00 1/20
SCHEMBL22528644 SCHEMBL22528644 1.00 1/20
SCHEMBL305411 SCHEMBL305411 0.75 1/20
Irisolone Irisolone (SCHEMBL242540) 0.73 1/20
Irisolone Irisolone (SCHEMBL29928854) 0.73 1/20
SCHEMBL668045 SCHEMBL668045 0.72 1/20
SCHEMBL2916013 SCHEMBL2916013 0.71 1/20
SCHEMBL29441847 SCHEMBL29441847 0.71 1/20
SCHEMBL29696493 SCHEMBL29696493 0.69 1/20
SCHEMBL2967226 SCHEMBL2967226 0.69 1/20
SCHEMBL2960859 SCHEMBL2960859 0.69 1/20
SCHEMBL2963278 SCHEMBL2963278 0.68 1/20
SCHEMBL2963281 SCHEMBL2963281 0.68 1/20
SCHEMBL2960667 SCHEMBL2960667 0.68 1/20
SCHEMBL2956891 SCHEMBL2956891 0.67 1/20
SCHEMBL966228 SCHEMBL966228 0.66 1/20
SCHEMBL2961264 SCHEMBL2961264 0.65 1/20
SCHEMBL7760763 SCHEMBL7760763 0.65 1/20
SCHEMBL1108362 SCHEMBL1108362 0.65 1/20
SCHEMBL669409 SCHEMBL669409 0.65 1/20

Clinical trials — most relevant to UGT1A8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity PHASE4COMPLETED
Cholestatic Drug-induced Liver Injury PHASE4UNKNOWN
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies PHASE4RECRUITING
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients PHASE2/PHASE3COMPLETED
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial PHASE3UNKNOWN
CBD for Pain Following Orthopedic Shoulder Surgery PHASE1/PHASE2RECRUITING
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma PHASE2NOT_YET_RECRUITING
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers PHASE1/PHASE2COMPLETED
Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer PHASE2NOT_YET_RECRUITING
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer PHASE2WITHDRAWN
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study PHASE2RECRUITING
Oral Cannabidiol for Opioid Withdrawal PHASE1/PHASE2COMPLETED
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer PHASE2COMPLETED
NALIRIFOX as Induction Therapy in LAPC PHASE2RECRUITING
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer PHASE2COMPLETED
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial PHASE2ACTIVE_NOT_RECRUITING
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 PHASE2RECRUITING
Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery PHASE2COMPLETED
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors PHASE1UNKNOWN
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours PHASE1UNKNOWN
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin PHASE1COMPLETED
Study of NK012 in Patients With Refractory Solid Tumors PHASE1COMPLETED
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors PHASE1COMPLETED
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors PHASE1COMPLETED
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas PHASE1WITHDRAWN
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C nanCOMPLETED
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype nanUNKNOWN
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a UGT1A8 binder may also engage these)

ProteinNameSimilarity
UGT1A9 UDP-glucuronosyltransferase 1A9 1.000 landscape →
UGT1A10 UDP-glucuronosyltransferase 1A10 1.000 landscape →
UGT1A7 UDP-glucuronosyltransferase 1A7 1.000 landscape →
Q64633 — 0.997 Q64633 →
Q62452 — 0.992 Q62452 →
Q6ZQM8 — 0.989 Q6ZQM8 →
Q64634 — 0.982 Q64634 →
UGT1A1 UDP-glucuronosyltransferase 1A1 0.957 landscape →
UGT1A3 UDP-glucuronosyltransferase 1A3 0.954 landscape →
UGT1A4 UDP-glucuronosyltransferase 1A4 0.950 landscape →
P35504 — 0.947 P35504 →
Q64550 — 0.946 Q64550 →
UGT1A6 UDP-glucuronosyltransferase 1A6 0.944 landscape →
Q63886 — 0.942 Q63886 →
Q64638 — 0.939 Q64638 →
P20720 — 0.936 P20720 →
Q28612 — 0.934 Q28612 →
Q64637 — 0.934 Q64637 →
Q64435 — 0.933 Q64435 →
P08430 — 0.930 P08430 →
B4F753 — 0.929 B4F753 →
Q4R766 — 0.927 Q4R766 →
Q9H3R1 — 0.927 Q9H3R1 →
P70691 — 0.927 P70691 →
O95803 — 0.927 O95803 →
Q6AYT7 — 0.927 Q6AYT7 →
Q9EQW8 — 0.927 Q9EQW8 →
Q9EQH7 — 0.926 Q9EQH7 →
Q99LR1 — 0.926 Q99LR1 →
B2GV54 — 0.924 B2GV54 →